Arca
Skip to content
Tools
Tools

Label Changes: Sertraline Hydrochloride Tablet, Film Coated (sertraline hydrochloride)

A drug's label (its prescribing information) is revised many times after approval: new warnings, new uses, new doses. DailyMed keeps every version. Pick a drug to see them all and what changed between any two.

Every version of the Sertraline Hydrochloride Tablet, Film Coated label DailyMed has published, from Physicians Total Care, Inc., and what changed between any two of them, section by section. Current label on DailyMed.

  • Versions on DailyMed: 7
  • Sections changed, version 7 to 8: 7

What changed from version 7 to version 8

Oct 31, 2012 to Feb 14, 2014, as published on DailyMed. Added text is underlined in green, removed text struck through in red.
  1. Dosage and administrationChanged · 263 words added, 24 removed
  2. ContraindicationsChanged · 104 words added, 23 removed
  3. WarningsChanged · 310 words added, 420 removed
  4. PrecautionsChanged · 212 words added, 467 removed
  5. How suppliedChanged · 91 words added, 114 removed
  6. Medication guideChanged · 39 words added, 23 removed
  7. Untitled sectionChanged · 12 words added, 14 removed

Dosage and administration

Changed263 words added, 24 removed
27 unchanged lines
The effectiveness of sertraline hydrochloride in long-term use, that is, for more than 3 menstrual cycles, has not been systematically evaluated in controlled trials. However, as women commonly report that symptoms worsen with age until relieved by the onset of menopause, it is reasonable to consider continuation of a responding patient. Dosage adjustments, which may include changes between dosage regimens (e.g., daily throughout the menstrual cycle versus during the luteal phase of the menstrual cycle), may be needed to maintain the patient on the lowest effective dosage and patients should be periodically reassessed to determine the need for continued treatment.
Switching Patients to or from a Monoamine Oxidase Inhibitor
Switching a Patient To or From a Monoamine Oxidase Inhibitor (MAOI) Intended to Treat Psychiatric Disorders
At least 14 days should elapse between discontinuation of an MAOI intended to treat psychiatric disorders and initiation of therapy with sertraline hydrochloride. In additionConversely, at least 14 days should be allowed after stopping sertraline hydrochloride before starting an MAOI intended to treat psychiatric disorders (see CONTRAINDICATIONS and WARNINGS).
Use of Sertraline Hydrochloride With Other MAOIs Such as Linezolid or Methylene Blue
Do not start sertraline hydrochloride in a patient who is being treated with linezolid or intravenous methylene blue because there is increased risk of serotonin syndrome. In a patient who requires more urgent treatment of a psychiatric condition, other interventions, including hospitalization, should be considered (see CONTRAINDICATIONS).
In some cases, a patient already receiving sertraline hydrochloride therapy may require urgent treatment with linezolid or intravenous methylene blue. If acceptable alternatives to linezolid or intravenous methylene blue treatment are not available and the potential benefits of linezolid or intravenous methylene blue treatment are judged to outweigh the risks of serotonin syndrome in a particular patient, sertraline hydrochloride should be stopped promptly, and linezolid or intravenous methylene blue can be administered. The patient should be monitored for symptoms of serotonin syndrome for 2 weeks or until 24 hours after the last dose of linezolid or intravenous methylene blue, whichever comes first. Therapy with sertraline hydrochloride may be resumed 24 hours after the last dose of linezolid or intravenous methylene blue (see WARNINGS).
The risk of administering methylene blue by non-intravenous routes (such as oral tablets or by local injection) or in intravenous doses much lower than 1 mg/kg with sertraline hydrochloride is unclear. The clinician should, nevertheless, be aware of the possibility of emergent symptoms of serotonin syndrome with such use (see WARNINGS).
Special Populations
2 unchanged lines
Treatment of Pregnant Women During the Third Trimester
Neonates exposed to sertraline hydrochloride and other SSRIs or SNRIs, late in the third trimester have developed complications requiring prolonged hospitalization, respiratory support, and tube feeding (see PRECAUTIONS). When treating pregnant women with sertraline hydrochloride during the third trimester, the physician should carefully consider the potential risks and benefits of treatment. The physician may consider tapering sertraline hydrochloride in the third trimester.
Discontinuation of Treatment with Sertraline Hydrochloride
4 unchanged lines

Contraindications

Changed104 words added, 23 removed
1 unchanged line
All Dosage Forms of sertraline hydrochloride
The use of MAOIs intended to treat psychiatric disorders with sertraline hydrochloride or within 14 days of stopping treatment with sertraline hydrochloride is contraindicated because of an increased risk of serotonin syndrome. The use of sertraline hydrochloride within 14 days of stopping an MAOI intended to treat psychiatric disorders is also contraindicated (see WARNINGS and DOSAGE AND ADMINISTRATION).
Starting sertraline hydrochloride in a patient who is being treated with MAOIs such as linezolid or intravenous methylene blue is also contraindicated because of an increased risk of serotonin syndrome (see WARNINGS and DOSAGE AND ADMINISTRATION).
Concomitant use in patients taking monoamine oxidase inhibitors (MAOIs) is contraindicated (see WARNINGS). Concomitant use in patients taking pimozide is contraindicated (see PRECAUTIONS).
Concomitant use in patients taking pimozide is contraindicated (see PRECAUTIONS).
Sertraline hydrochloride is contraindicated in patients with a hypersensitivity to sertraline or any of the inactive ingredients in sertraline hydrochloride.
2 unchanged lines

Warnings

Changed310 words added, 420 removed
20 unchanged lines
A major depressive episode may be the initial presentation of bipolar disorder. It is generally believed (though not established in controlled trials) that treating such an episode with an antidepressant alone may increase the likelihood of precipitation of a mixed/manic episode in patients at risk for bipolar disorder. Whether any of the symptoms described above represent such a conversion is unknown. However, prior to initiating treatment with an antidepressant, patients with depressive symptoms should be adequately screened to determine if they are at risk for bipolar disorder; such screening should include a detailed psychiatric history, including a family history of suicide, bipolar disorder, and depression. It should be noted that sertraline hydrochloride is not approved for use in treating bipolar depression.
Cases of serious sometimes fatal reactions have been reported in patients receiving sertraline hydrochloride, a selective serotonin reuptake inhibitor (SSRI), in combination with a monoamine oxidase inhibitor (MAOI). Symptoms of a drug interaction between an SSRI and an MAOI include: hyperthermia, rigidity, myoclonus, autonomic instability with possible rapid fluctuations of vital signs, mental status changes that include confusion, irritability, and extreme agitation progressing to delirium and coma. These reactions have also been reported in patients who have recently discontinued an SSRI and have been started on an MAOI. Some cases presented with features resembling neuroleptic malignant syndrome. Therefore, sertraline hydrochloride should not be used in combination with an MAOI, or within 14 days of discontinuing treatment with an MAOI. Similarly, at least 14 days should be allowed after stopping sertraline hydrochloride before starting an MAOI.
The concomitant use of sertraline hydrochloride with MAOIs intended to treat depression is contraindicated (see CONTRAINDICATIONS and WARNINGS – Potential for Interaction with Monoamine Oxidase Inhibitors).
Serotonin Syndrome or Neuroleptic Malignant Syndrome (NMS)-like Reactions
Serotonin Syndrome
The development of a potentially life-threatening serotonin syndrome has been reported with SNRIs and SSRIs, including sertraline hydrochloride, alone but particularly with concomitant use of other serotonergic drugs (including triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, tryptophan, buspirone, and St. John's Wort) and with drugs that impair metabolism of serotonin (in particular, MAOIs, both those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue).
The development of a potentially life-threatening serotonin syndrome or Neuroleptic Malignant Syndrome (NMS)-like reactions have been reported with SNRIs and SSRIs alone, including Sertraline hydrochloride treatment, but particularly with concomitant use of serotonergic drugs (including triptans and fentanyl) with drugs which impair metabolism of serotonin (including MAOIs), or with antipsychotics or other dopamine antagonists. Serotonin syndrome symptoms may include mental status changes (e.g., agitation, hallucinations, coma), autonomic instability (e.g., tachycardia, labile blood pressure, hyperthermia), neuromuscular aberrations (e.g., hyperreflexia, incoordination) and/or gastrointestinal symptoms (e.g., nausea, vomiting, diarrhea). Serotonin syndrome, in its most severe form can resemble neuroleptic malignant syndrome, which includes hyperthermia, muscle rigidity, autonomic instability with possible rapid fluctuation of vital signs, and mental status changes. Patients should be monitored for the emergence of serotonin syndrome or NMS-like signs and symptoms.
Serotonin syndrome symptoms may include mental status changes (e.g., agitation, hallucinations, delirium, and coma), autonomic instability (e.g., tachycardia, labile blood pressure, dizziness, diaphoresis, flushing, hyperthermia), neuromuscular symptoms (e.g., tremor, rigidity, myoclonus, hyperreflexia, incoordination) seizures, and/or gastrointestinal symptoms (e.g., nausea, vomiting, diarrhea). Patients should be monitored for the emergence of serotonin syndrome
The concomitant use of Sertraline hydrochloride with MAOIs intended to treat depression is contraindicated.
If concomitant treatment of Sertraline hydrochloride with a 5-hydroxytryptamine receptor agonist (triptan) is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases.
The concomitant use of Sertraline hydrochloride with serotonin precursors (such as tryptophan) is not recommended.
The concomitant use of sertraline hydrochloride with MAOIs intended to treat psychiatric disorders is contraindicated. Sertraline hydrochloride should also not be started in a patient who is being treated with MAOIs such as linezolid or intravenous methylene blue. All reports with methylene blue that provided information on the route of administration involved intravenous administration in the dose range of 1 mg/kg to 8 mg/kg. No reports involved the administration of methylene blue by other routes (such as oral tablets or local tissue injection) or at lower doses. There may be circumstances when it is necessary to initiate treatment with a MAOI such as linezolid or intravenous methylene blue in a patient taking sertraline hydrochloride. Sertraline hydrochloride should be discontinued before initiating treatment with the MAOI (see CONTRAINDICATIONS and DOSAGE AND ADMINISTRATION).
If concomitant use of sertraline hydrochloride with other serotonergic drugs including triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, buspirone, tryptophan, and St. John's Wort is clinically warranted, patients should be made aware of a potential increased risk for serotonin syndrome, particularly during treatment initiation and dose increases.
Treatment with Sertralinesertraline hydrochloride and any concomitant serotonergic or antidopaminergic agents, including antipsychotics, should be discontinued immediately if the above events occur and supportive symptomatic treatment should be initiated.
Co-administration of ZOLOFT with other drugs which enhance the effects of serotonergic neurotransmission, such as tryptophan, fenfluramine, fentanyl, 5-HT agonists, or the herbal medicine St. John's Wort (hypericum perforatum) should be undertaken with caution and avoided whenever possible due to the potential for pharmacodynamic interaction.

Precautions

Changed212 words added, 467 removed
12 unchanged lines
SSRIs and SNRIs, including sertraline hydrochloride, may increase the risk of bleeding events. Concomitant use of aspirin, nonsteroidal anti-inflammatory drugs, warfarin, and other anticoagulants may add to this risk. Case reports and epidemiological studies (case-control and cohort design) have demonstrated an association between use of drugs that interfere with serotonin reuptake and the occurrence of gastrointestinal bleeding. Bleeding events related to SSRIs and SNRIs use have ranged from ecchymoses, hematomas, epistaxis, and petechiae to life-threatening hemorrhages.
Patients should be cautioned about the risk of bleeding associated with the concomitant use of Sertralinesertraline hydrochloride and NSAIDs, aspirin, or other drugs that affect coagulation.
Weak Uricosuric Effect
7 unchanged lines
Interference with Cognitive and Motor Performance
In controlled studies, sertraline hydrochloride did not cause sedation and did not interfere with psychomotor performance. (See Information for Patients. ).
Hyponatremia
6 unchanged lines
Information for Patients
Prescribers or other health professionals should inform patients, their families, and their caregivers about the benefits and risks associated with treatment with sertraline hydrochloride and should counsel them in its appropriate use. A patient Medication Guide about "Antidepressant Medicines, Depression and other Serious Mental Illness, and Suicidal Thoughts or Actions": is available for sertraline hydrochloride. The prescriber or health professional should instruct patients, their families, and their caregivers to read the Medication Guide and should assist them in understanding its contents. Patients should be given the opportunity to discuss the contents of the Medication Guide and to obtain answers to any questions they may have. The complete text of the Medication Guide is reprinted at the end of this document.
Patients should be advised of the following issues and asked to alert their prescriber if these occur while taking sertraline hydrochloride.
10 unchanged lines
Sertraline hydrochloride oral concentrate contains 20 mg/mL of sertraline (as the hydrochloride) as the active ingredient and 12% alcohol. Sertraline hydrochloride oral concentrate must be diluted before use. Just before taking, use the dropper provided to remove the required amount of sertraline hydrochloride oral concentrate and mix with 4 oz (1/2 cup) of water, ginger ale, lemon/lime soda, lemonade or orange juice ONLY. Do not mix sertraline hydrochloride oral concentrate with anything other than the liquids listed. The dose should be taken immediately after mixing. Do not mix in advance. At times, a slight haze may appear after mixing; this is normal. Note that caution should be exercised for persons with latex sensitivity, as the dropper dispenser contains dry natural rubber.
Angle-Closure Glaucoma
SSRIs including sertraline may have an effect on pupil size resulting in mydriasis. This mydriatic effect has the potential to narrow the eye angle resulting in increased intraocular pressure and angle-closure glaucoma, especially in patients pre-disposed. Sertraline should therefore be used with caution in patients with angle-closure glaucoma or history of glaucoma.
Laboratory Tests
16 unchanged lines
Monoamine Oxidase Inhibitors
See CONTRAINDICATIONS and WARNINGS.
See CONTRAINDICATIONS, WARNINGS, and DOSAGE AND ADMINISTRATION.
Drugs Metabolized by P450 3A4
3 unchanged lines
Serotonergic Drugs
Based on the mechanism of action of SNRIs and SSRIs, including sertraline hydrochloride, and the potential for serotonin syndrome, caution is advised when SNRIs and SSRIs, including sertraline hydrochloride, are coadministered with other drugs that may affect the serotonergic neutrotransmitter systems, such as triptans, linezolid (an antibiotic which is a reversible non-selective MAOI), lithium, tramadol, or St. John's Wort (see WARNINGS-Serotonin Syndrome). The concomitant use of sertraline hydrochloride with other SSRIs, SNRIs or tryptophan is not recommended (see PRECAUTIONS – Drug Interactions).
See CONTRAINDICATIONS, WARNINGS, and DOSAGE AND ADMINISTRATION.
Triptans
27 unchanged lines
Pregnancy-Nonteratogenic Effects
Neonates exposed to sertraline hydrochloride and other SSRIs or serotonin and norepinephrine reuptake inhibitors (SNRIs), late in the third trimester have developed complications requiring prolonged hospitalization, respiratory support, and tube feeding. These findings are based on post marketing reports. Such complications can arise immediately upon delivery. Reported clinical findings have included respiratory distress, cyanosis, apnea, seizures, temperature instability, feeding difficulty, vomiting, hypoglycemia, hypotonia, hypertonia, hyperreflexia, tremor, jitteriness, irritability, and constant crying. These features are consistent with either a direct toxic effect of SSRIs and SNRIs or, possibly, a drug discontinuation syndrome. It should be noted that, in some cases, the clinical picture is consistent with serotonin syndrome (see WARNINGS: Serotonin Syndrome).
Infants exposed to SSRIs in late pregnancy may have an increased risk for persistent pulmonary hypertension of the newborn (PPHN). PPHN occurs in 1–2 per 1,000 live births in the general population and is associated with substantial neonatal morbidity and mortality. In a retrospective case-control study of 377 women whose infants were born with PPHN and 836 women whose infants were born healthy, the risk for developing PPHN was approximately sixfold higher for infants exposed to SSRIs after the 20th week of gestation compared to infants who had not been exposed to antidepressants during pregnancy. There is currently no corroborative evidence regarding the risk for PPHN following exposure to SSRIs in pregnancy; this is the first study that has investigated the potential risk. The study did not include enough cases with exposure to individual SSRIs to determine if all SSRIs posed similar levels of PPHN risk.
Infants exposed to SSRIs in pregnancy may have an increased risk for persistent pulmonary hypertension of the newborn (PPHN). PPHN occurs in 1– 2 per 1,000 live births in the general population and is associated with substantial neonatal morbidity and mortality. Several recent epidemiologic studies suggest a positive statistical association between SSRI use (including sertraline hydrochloride) in pregnancy and PPHN. Other studies do not show a significant statistical association.
When treating a pregnant woman with Sertraline hydrochloride during the third trimester, the physician should carefully consider both the potential risks and benefits of treatment (see DOSAGE AND ADMINISTRATION). Physicians should note that in a prospective longitudinal study of 201 women with a history of major depression who were euthymic in the context of antidepressant therapy at the beginning of pregnancy, women who discontinued antidepressant medication during pregnancy were more likely to experience a relapse of major depression than women who continued antidepressant medication.
Physicians should also note the results of a prospective longitudinal study of 201 pregnant women with a history of major depression, who were either on antidepressants or had received antidepressants less than 12 weeks prior to their last menstrual period, and were in remission. Women who discontinued antidepressant medication during pregnancy showed a significant increase in relapse of their major depression compared to those women who remained on antidepressant medication throughout pregnancy.
When treating a pregnant woman with sertraline hydrochloride, the physician should carefully consider both the potential risks of taking an SSRI, along with the established benefits of treating depression with an antidepressant. This decision can only be made on a case by case basis (see DOSAGE AND ADMINISTRATION).
Labor and Delivery
13 unchanged lines
SSRIS and SNRIs, including sertraline hydrochloride, have been associated with cases of clinically significant hyponatremia in elderly patients, who may be at greater risk for this adverse event (see PRECAUTIONS, Hyponatremia).
Diabetes/Loss of Glycemic Control
Cases of new onset diabetes mellitus have been reported in patients receiving SSRIs including ZOLOFT. Loss of glycemic control including both hyperglycemia and hypoglycemia has also been reported in patients with and without pre-existing diabetes. Patients should therefore be monitored for signs and symptoms of glucose fluctuations. Diabetic patients especially should have their glycemic control carefully monitored since their dosage of insulin and/or concomitant oral hypoglycemic drug may need to be adjusted.

How supplied

Changed91 words added, 114 removed
2 unchanged lines
Sertraline hydrochloride 25 mg tablets: light green capsular-shaped scored tablets engraved on one side with G 4960 and on the other side engraved with 25 mg.
NDC 54868-5658-0 Bottles of 30 NDC 54868-5658-1 Bottles of 60
NDC 54868-5658-0 | Bottles of 30
NDC 54868-5658-1 | Bottles of 60
NDC 54868-5658-2 | Bottles of 90
Sertraline hydrochloride 50 mg tablets: light blue capsular-shaped scored tablets engraved on one side with G 4900 and on the other side engraved with 50 mg.
NDC 54868-5639-2 Bottles of 10 NDC 54868-5639-4 Bottles of 15 NDC 54868-5639-0 Bottles of 30 NDC 54868-5639-1 Bottles of 45 NDC 54868-5639-6 Bottles of 60 NDC 54868-5639-5 Bottles of 90 NDC 54868-5639-3 Unit Dose Package of 100
NDC 54868-5639-2 | Bottles of 10
NDC 54868-5639-0 | Bottles of 30
NDC 54868-5639-1 | Bottles of 45
NDC 54868-5639-6 | Bottles of 60
NDC 54868-5639-5 | Bottles of 90
Sertraline hydrochloride 100 mg tablets: light yellow capsular-shaped scored tablets engraved on one side with G 4910 and on the side engraved with 100 mg.
NDC 54868-5638-2 Bottles of 15 NDC 54868-5638-1 Bottles of 30 NDC 54868-5638-0 Bottles of 60 NDC 54868-5638-6 Bottles of 90 NDC 54868-5638-5 Bottles of 100 NDC 54868-5638-8 Bottles of 135 NDC 54868-5638-7 Bottles of 180
NDC 54868-5638-1 | Bottles of 30
NDC 54868-5638-0 | Bottles of 60
NDC 54868-5638-6 | Bottles of 90
NDC 54868-5638-5 | Bottles of 100
NDC 54868-5638-7 | Bottles of 180
Store at 25°C (77°F); excursions permitted to 15° – 30°C (59° – 86°F)[see USP Controlled Room Temperature].
1 unchanged line

Medication guide

Changed39 words added, 23 removed
10 unchanged lines
Call your healthcare provider right away if you have any of the following symptoms, or call 911 if an emergency. SERTRALINE HYDROCHLORIDE may be associated with these serious side effects:
2. Serotonin Syndrome or Neuroleptic Malignant Syndrome-like reactions. This condition can be life-threatening and may include:
agitation, hallucinations, coma or other changes in mental status coordination problems or muscle twitching (overactive reflexes) racing heartbeat, high or low blood pressure sweating or fever nausea, vomiting, or diarrhea muscle rigidity
26 unchanged lines
take Antabuse® (disulfiram) (if you are taking the liquid form of SERTRALINE HYDROCHLORIDE) due to the alcohol content.
take a Monoaminemonoamine Oxidaseoxidase Inhibitorinhibitor (MAOI). Ask your healthcare provider or pharmacist if you are not sure if you take an MAOI, including the antibiotic linezolid. Do not take an MAOI within 2 weeks of stopping SERTRALINE HYDROCHLORIDE unless directed to do so by your physician. Do not start SERTRALINE HYDROCHLORIDE if you stopped taking an MAOI in the last 2 weeks unless directed to do so by your physician. People who take SERTRALINE HYDROCHLORIDE close in time to an MAOI may have serious or even life-threatening side effects. Get medical help right away if you have any of these symptoms: high fever uncontrolled muscle spasms stiff muscles rapid changes in heart rate or blood pressure confusion loss of consciousness (pass out)
What should I tell my healthcare provider before taking SERTRALINE HYDROCHLORIDE? Ask if you are not sure.
52 unchanged lines
This Medication Guide summarizes the most important information about SERTRALINE HYDROCHLORIDE. If you would like more information, talk with your healthcare provider. You may ask your healthcare provider or pharmacist for information about SERTRALINE HYDROCHLORIDE that is written for healthcare professionals.
For more information about SERTRALINE HYDROCHLORIDE call 1-800-438-1985.
For more information about sertraline hydrochloride call 1 800 438 1985 or go to www.greenstonellc.com
What are the ingredients in SERTRALINE HYDROCHLORIDE?
4 unchanged lines
This Medication Guide has been approved by the U.S. Food and Drug Administration
LAB-0541-24.0
January 2012
February 2013

Untitled section

Changed12 words added, 14 removed
Rx only
LAB-0340-1820.0
January 2012
February 2013
Relabeling and Repackaging by: Physicians Total Care, Inc. Tulsa, Oklahoma 74146
Distributed by: Physicians Total Care, Inc. Tulsa, OK 74146

Unchanged: Boxed warning, Description, Clinical pharmacology, Indications and usage, Adverse reactions, Drug abuse and dependence, Overdosage, PRINCIPAL DISPLAY PANEL - 25 mg Tablet Bottle Label, PRINCIPAL DISPLAY PANEL - 50 mg Tablet Bottle Label, PRINCIPAL DISPLAY PANEL - 100 mg Tablet Bottle Label.

Every version

7 versions of set dfc0d446-cdc0-402b-a094-eae9f1115508, newest first.
VersionPublished on DailyMedCompareSPL file
8Feb 14, 2014Shown belowDownload .zip
7Oct 31, 2012With version 6Download .zip
6Jun 27, 2012With version 5Download .zip
5Apr 12, 2012With version 4Download .zip
4Jan 18, 2012With version 2Download .zip
2Jul 21, 2011With version 1Download .zip
1May 28, 2010First versionDownload .zip

Read an SPL file

Open an SPL label file

Drop a Structured Product Labeling .xml file, or the .zip DailyMed downloads, to read it as a label. It is read in this browser tab and not uploaded.

Read in this browser tab; nothing is uploaded.

Versions and label text from DailyMed's SPL web services; a version's text is read from its SPL file, so it matches what DailyMed shows. Recent safety-related changes from FDA's Safety-related Labeling Changes database, which covers NDAs and CDER biologics, not generics. Lists refresh daily. DailyMed, National Library of Medicine

About label change history

How to read a comparison

Sections that changed come first, in the order a reviewer reads a label: boxed warning, recent major changes, indications, dosage, contraindications, warnings and precautions, adverse reactions, then the rest. Each shows the changed lines with one unchanged line either side; longer unchanged stretches are folded into a count. Table rows read left to right with cells separated by a bar.

The comparison covers the label text. Images, product data (NDC codes, ingredients, packaging) and formatting are not compared.

Which label is shown

A drug can have several labels: one per brand-name application (Ozempic, Wegovy and Rybelsus are three), and copies from repackagers. For each NDA or BLA the page takes the DailyMed set with the most versions, which is the application holder's. Generic labels are left out; they follow the brand's label.

Frequently asked questions

Where do the versions come from?
DailyMed, the National Library of Medicine's library of labels in Structured Product Labeling (SPL) format. Each time a company submits a revised label, DailyMed publishes it as a new version of the same set and keeps the old ones.
Is a new version a new FDA approval?
Not always. Companies also submit new versions for changes that need no FDA approval first, such as a new address, a new package size or a corrected typo. Safety changes FDA approved are listed in its Safety-related Labeling Changes database, linked below.
Why does the published date differ from the label's revised date?
The published date is when DailyMed posted the version. The label's own revised date, at the end of the highlights, is when the company revised the text, usually a few days to weeks earlier.
How is the comparison made?
Each section is matched by its standard LOINC code, then split into headings, paragraphs, list items and table rows. Lines are aligned with a longest-common-subsequence diff; a removed and an added line that share at least half their words are shown as one edited line with the changed words marked. Curly quotes, dash styles and spacing are ignored.
Is my SPL file uploaded?
No. A file you drop on this page is read in your browser tab and never sent to Arca.
Esc

Type a name: a tool, a company, a drug or brand, a condition, a gene or a state. Identifiers like K231234, NCT05012345 or NDA 215866 open their record.

Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.